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Abstract 
Adipocytic-cytosolic non-receptor p otein tyrosine kinase (CytPTK) when activated can substitute for the insulin receptor tyrosine 
kinase (InsRTK), in manifi~sting several insulin effects in insulin-receptor independent fashion. Our aims here were to utilize 
PolyGlu4Tyr, a good experimental exogenous ubstrate for protein tyrosine kinases (PTKs) in general, for studying qualitative and 
quantitative parameters of CytPTKs extracted from different issue cytosols. At the same time, we would search for a unique specific 
marker specifically characterizing CytPTKs. High speed supernatants of spleen, thymus, smooth muscle, lung and kidney were found to 
be rich in CytPTK activitie,;. Their specific activities being 6- to 13-fold that of liver or adipose cytosols. Brain, testis and adrenal 
cytosols were an intermediate source of CytPTK activity, whereas CytPTK activity of heart and skeletal muscle was low. It was also 
evaluated that the capacity of the cytosol to phosphorylate PolyGlunTyr is 15-50% that of the non-stimulated Triton X-100 extractable 
plasma membrane PTKs. Fractionation of the cytosols on superose 12 column revealed several CytPTKs within the same tissue, their 
peaks ranging between 30 and 450 kDa. Immunoblotting analysis howed Fyn and Lyn were present in most tissue cytosols. Upon 
immunoprecipitation, however, with anti-Fyn or anti-Lyn, negligible amounts (< 2%) of the total cellular CytPTK were precipitated. 
Thus, these general marker,; of CytPTKs comprise only a minor proportion of the total intracellular PolyGlu4Tyr phosphorylating 
capacity. To see whether a specific marker for CytPTK could be detected, we also examined the requirement of CytPTKs for divalent 
ions, their preferred phosphate donor and their sensitivity to inhibition by known PTK inhibitors. We found that the order of reactivity 
with divalent cations was Co2÷> Mn2+> Mg 2+, while Zn 2+ and Ca 2+ did not support CytPTK activity. The best phosphate donor was 
ATP (EDso = 5 /xM), but other nucleoside 3-phosphates could substitute for ATP at high concentrations. With respect o these 
parameters, no basic difference xists between cytosolic and plasma-membrane PTKs. The PTK inhibitors, genestein and quercetin, 
inhibited both cytosolic and membranal PTKs at micromolar concentrations. In contrast, staurosporine was a potent inhibitor of CytPTKs 
(IC50 5-20 nM) and a poor inhibitor of membranal PTKs (ICso 10-40/xM). One of the conclusions we can draw from this study is that 
tissue cytosols contain PolyGlu4Tyr phosphorylating capacity in quantities greater than previously assumed and that the low level of 
phosphotyrosine found in cells is not the result of limited intracellular levels of CytPTKs. 
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1. Introduction 
Until recently, non-receptor (water-soluble), cytosolic 
protein tyrosine kinases (CytPTKs) attracted little atten- 
tion. Interest was sparked when several igands, following 
Abbreviations: PTK, protein tyrosine kinase; M-PTK, membranal 
protein tyrosine kinase; CytPTK, cytosolic protein tyrosine kinase; In- 
sRTK, insulin receptor tyrosine kinase; PolyGlu4Tyr, 
poly[(GluNa:Tyr)4:1]; WGA, wheat germ agglutinin; HPLC, high perfor- 
mance liquid chromatography; PTPase, protein phosphotyrosine phos- 
phatase. 
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receptor binding, were found to induce rapid endogenous 
tyrosine phosphorylation, though the receptors were devoid 
of intrinsic PTK activity [1-3]. We have recently found 
that a non-receptor adipocytic PTK, when activated, can 
facilitate several of the bioeffects of insulin, in an insulin- 
receptor-independent fashion [4-6]. Receptor-PTKs, such 
as that of EGF or PDGF could also activate non-receptor 
PTKs [7-9]. Sequences of several CytPTKs have been 
elucidated [10] but progress is slow because information 
about their specific intracellular substrates i limited. How- 
ever, among exogenous ubstrates examined, PolyGlu4Tyr, 
a random copolymer containing L-glutamic acid and L- 
tyrosine at a 4:1 molar ratio, has been found to be fairly 
good for most CytPTKs [1 1]. Therefore, PolyGlu4Tyr may 
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be a common denominator and useful for comparing dif- 
ferent CytPTKs. 
Our aims here were to determine the main features 
common to a large variety of rat-tissue CytPTKs such as 
their preference todivalent cations, their molecular weights, 
and their sensitivity to PTK inhibitors. It was also of great 
interest to us to evaluate whether CytPTKs possess a basic 
inherited feature(s) not shared by intrinsic (detergent solu- 
ble) membranal PTKs (M-PTKs). Finally, based on their 
molecular weight range, we set out to investigate whether 
previously identified soluble PTKs such as Lyn and Fyn 
comprise a large fraction of the intracellular PolyGlu4Tyr 
phosphorylating capacity. 
2. Materials and methods 
2.1. Materials 
PolyGlu4Tyr was purchased from Sigma. Monoclonal 
antibodies to phosphotyrosine w re obtained from Mono- 
Yeda (Rehovot, Israel), rabbit polyclonal antibodies to Lyn 
and Fyn were purchased from Santa Cruz Biotechnology 
(Santa Cruz, USA). Protein A conjugated with horseradish 
peroxidase, nhanced chemiluminescence W stern blot de- 
tection systems and sepharose protein A were purchased 
from Amersham Corp (UK). Superose 12 column was 
purchased from Pharmacia LKB Biotechnology (Uppsala, 
Sweden). 
2.2. Procedures 
Solubilized membranal proteins and partially purified 
insulin receptors were prepared from different issues fol- 
lowing homogenization as described below for the super- 
natant fraction solubilization with 1% Triton X-100 of the 
particulate fraction and removal of the non-solubilized 
fraction by centrifugation at 100000 X g for 60 min. 
Insulin receptors from rat liver were further affinity puri- 
fied on a WGA-agarose column [I 2]. 
Preparation of high speed supernatant fractions from 
various tissues. Rat adipocytes, rat liver, and other organs 
used here were excised and homogenized (in the absence 
of detergents) with a polytron homogenizer in 25 mM 
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Fig. 1. Requirement of cytosolic protein tyrosine kinases for divalent cations. CytPTK activity from different issues was measured in the presence of 1 
mM cobalt (Co), 1 mM manganese (Mn), 1 mM magnesium (Mg), 1 mM cobalt and magnesium (Co + Mg) or in the absence of divalent cations. One 
hundred percent activity is taken as that obtained in the presence of 1 mM cobalt. 
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Hepes (pH 7.4) containing 0.25 M sucrose and a cocktail 
of protease inhibitors. The cell or tissue homogenates were 
then centrifuged at 12 000 X g for 20 min and the super- 
natant was further centrifilged at 100 000 × g for 60 min. 
The supernatant fractions were stored at -137°C until 
used. 
Tyrosine kinase activity measurements. The standard 
enzyme assay mixture (final volume 60 /zl in 50 mM 
Hepes buffer, pH 7.4) contained a CytPTK source (1-5 
/xg protein from the high speed supernatant fractions), 
divalent cations (specified in the text for each figure) and 
100 /xM ATP. The reaction was initiated by adding Poly- 
Glu4Tyr (final concentration 0.1 mg/ml), allowed to pro- 
ceed for 30 min at 22°C, and terminated by adding EDTA 
(20 mM). Basically, the same procedure was applied for 
PolyGlu4Tyr phosphorylating activity both of WGA 
agarose-purified InsRTK and of solubilized membranal 
proteins (0.25-1.0 ~g), but Triton X-100 (0.1%) was 
added to the assay mixture. Insulin (10 -7  M) was added to 
the InsRTK assay. 
Phosphotyrosine content in PolyGlu4Tyr was quanti- 
tated by a radioimmunoassay procedure according to Ref. 
[13]. This assay utilized specific monoclonal antibodies to 
phosphotyrosine (final dilution 1:100,000) and t25I-BSA- 
phosphotyrosine conjugate. 
Western blot analyses were carried out by transferring 
proteins to nitrocellulose membranes [14]. These were 
sequentially treated with polyclonal antibodies to Fyn or 
Lyn and with protein A-horseradish peroxidase conjugate, 
and finally subjected to enhanced chemiluminescence 
Western blot detection system, as described in detail in the 
Manufacturer's protocol. 
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Fig. 2. Specificity of CytPTKs to nucleoside-3-phosphate donors. Liver 
CytPTK activity in the presence ,of various concentrations of ATP and 1 
mM of either GTP, UTP, CTP or TTP. The CytPTK activities are 
supported with 1 mM cobalt in the presence of different nucleoside 
3-phosphate donors. One hundred percent activity is taken as that ob- 
tained with 100 IxM ATP. 
Fractionation of rat tissue cytosols by size exclusion 
chromatography. The cytosols (0.2 ml, 2-4 mg protein) 
were fractionated by HPLC equipped with Superose 12 
column (1 X 30 cm). The column was equilibrated and 
developed with 25 mM Hepes buffer (pH 7.4)-150 mM 
NaCI, at a rate of 0.5 ml/min. Fractions of 0.5 ml each 
were collected. 
Protein concentration was determined by the method of 
Bradford [15]. 
3. Results 
3.1. Divalent cations and best phosphate donors for cy- 
tosolic protein tyrosine kinases 
Of all the divalent ions studied, cobalt proved the most 
effective in supporting CytPTK activities in each of the 
tissues examined (Fig. 1), Mn 2+ was the second most 
effective cation in some tissues (spleen, thymus and smooth 
muscle) being more responsive than others (heart, brain 
adipose and testis) Mg 2+ by itself was the least effective, 
but it synergized with Co 2+ and with Mn 2÷. Other diva- 
lent cations, such as zinc and calcium did not promote 
CytPTK activation at all (not shown). 
ATP was the best phosphorylating a ent in promoting 
phosphorylation. Half maximal activation under optimal 
experimental conditions were obtained with 5 ~M ATP 
using adipose and liver CytPTK. GTP could also serve as a 
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Fig. 3. Levels of CytPTKs in various tissue cytosols. The assay was 
performed in 60 /.d of 50 mM Hepes buffer (pH 7.4), containing 2 ixg 
protein derived from the indicated, high-speed supernatant-tissue extracts; 
1 mM Co 2+, 100 /~M ATP and 0.1 mg/ml  PolyGlu4Tyr. Results are 
presented as units//xg protein. One unit will incorporate 11 picomoles 
phosphotyrosine p r 20 min at 22°C into 5 /xg PolyGlu4Tyr under the 
assay conditions. 
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phosphate donor but had ~ 10% the potency of ATP. 
Other nucleosides 3-phosphate donors such as UTP, CTP 
or TTP had only ~ 1% the potency of ATP. The results 
with respect o the liver CytPTK are shown in Fig. 2. 
3.2. Distribution of CytPTK in rat tissue cytosols 
Fig. 3 shows the specific activities per /xg protein of 
CytPTKs derived from a large variety of rat tissues. For 
the sake of comparison, we took liver CytPTK as a 
reference point. Cytosolic PTK activities were very high in 
the spleen, thymus, smooth muscle, lung and kidney (6-to 
13-fold that of liver CytPTK), moderately higher (1.5- to 
3.5-fold) in brain, testis and adrenal and about he same in 
adipose and pancreas. Heart cytosol was a poor source of 
CytPTK (0.5 times that of liver CytPTK) and skeletal 
muscle was nearly or completely devoid of CytPTK activ- 
ity. 
3.3. Effects of established PTK inhibitors on CytPTK 
activities 
The results in Fig. 4 demonstrate he potency of estab- 
lished PTK inhibitors against several CytPTKs. Stau- 
rosporine was without exception the most powerful, effec- 
tively inhibiting in the nanomolar concentration range (Fig. 
4). Quercetin and genestein also inhibited CytPTKs but 
only at micromolar concentrations, while herbamycin was 
ineffective. Thus, staurosporine is about three orders of 
magnitude more potent han any other inhibitor tested. 
Table 1 
Inhibition of CytPTKs by staurosporine 
Tissue source MW Staurosporine 
of CytPTK (kDa) inhibition 
IC 50 (nM) 
Adipose 54 4.0 + 0.8 
Spleen 500 2.1 +0.3 
54 3.6 + 0.8 
Kidney 54 6.2 + 0.9 
Lung 54 3.1 _ 0.7 
Brain 500 4.5 + 0.9 
42 6.0 + 0.9 
Thymus 500 4.3 + 0.4 
54 3.8 +_ 0.4 
Heart 54 3.3 + 0.9 
Pancreas 54 5.5 + 0.9 
Liver 54 6.5 + 0.8 
Testis 150 15.5 _ 2.1 
42 18.0 +_ 2.5 
Smooth muscle 54 7.5 + 0.8 
Rat tissue cytosols were fractionated onsuperose 12 column and each 
tube was measured for tyrosine kinase activity. Molecular weight of peak 
activity was calculated, and each peak was treated with staurosporine 
under experimental conditions specified in the legend to Fig. 3. 
3.4. Fractionation of tissue cytosol according to molecular 
weight distribution 
To analyze molecular weight distribution, CytPTKs from 
different tissues were fractionated by an HPLC system 
equipped with superose 12 column, previously calibrated 
with molecular-weight protein markers. Each fraction was 
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Fig. 4. Inhibition of CytPTK activities by PTK inhibitors: the assay was performed under the experimental conditions specified inthe legend to Fig. 3, in 
the absence and the presence ofthe indicated concentrations f taurosporine (O), quercetin (0) and genestein ([]). 
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Fig. 5. Distribution of cytosolic PTKs according to molecular weights. Cytosols from various tissues were fractionated on superose 12 column 
(experimental procedure). Each fraction was examined for its PolyGlugTyr phosphorylating activity. Arrows on the top of the figure show the M.W. of 
markers eluted on the same column under similar experimental conditions. 
Table 2 
Membranal versus cytosolic distribution of PolyGlu4Tyr phosphorylating capacity from several representative tissues 
PolyGlu4Tyr phosphorylating capacity 
Distribution among compartments 2 
Tissue source Cytosalic membranal Cytosolic Membranal Membranal/ 
units//zg protein i % % cytosolic 
ratio 
Liver 0.9 30.6 11 89 8.1 
Cardiac 0.5 28.8 13 87 6.7 
Adipose 0.9 19.8 18 82 4.6 
Spleen 9 99.0 26 74 2.85 
Kidney 4.5 28.8 49 51 1.04 
i 1 Unit is 11 picomol of PTyr incorporated into 5 /zg PolyGlu4Tyr per 20 rain at 24°C under the standard assay conditions and in the presence of Co 2+ ,
Mg 2+ and Mn 2+ (1 mM each). 
2 Estimation is based on homogenizing 1 g of each given tissue, and quantitative separation into 100000 x g supernatant (cytosolic-compartment) a d
plasma membrane compartment (Triton X-100 solubilized pellet). 
Each fraction was evaluated for specific activity, protein content and total PolyGlu4Tyr phosphorylating capacity. Results are expressed as percentage of 
each fraction where the sum of both is taken as 100%. 
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examined for its PolyGluaTyr phosphorylating activity. As 
can be seen in Fig. 5, cytosolic-PolyGluaTyr phosphorylat- 
ing activity was stretched over a wide range of molecular 
weights indicating the presence of several PTK species 
within the same tissue. All cytosols, however, appear to 
have their major PTK activity in the range of M.W. = 42- 
54 kDa and in some tissues (spleen, brain, thymus) a high 
molecular weight CytPTK (~ 500 kDa) was also present 
(Table 1). There was one distinct exception: adipose cy- 
tosol seems to contain predominantly a single CytPTK 
species of M.W. = 53 _ 3 kDa (Fig. 5, and Ref. 4). 
We then examined the inhibitory potency of stau- 
rosporine on each peak individually. It inhibited all CytP- 
TKs, with IC50 values ranging from 2 to 7.5 nM. The 
exception was testis CytPTK with an IC50 = 17 _ 2 nM. 
Table 4 
CytPTK activity following immunoprecipitation of Fyn and Lyn 
Activity Activity remaining after 
immunoprecipitation with 
Tissue source ct Fyn a Lyn 
Adipose 1.1 _+0.1 1.0_+0.2 1.1 _+0.1 
Liver 1.4+0.1 1.34-0.1 1.4_+0.1 
Kidney 6.4 + 0.6 6.4 + 0.2 6.4 + 0.2 
Spleen 14.1 ___ 1.2 12.8_+0.4 14.8_+0.8 
The results are presented as units//xg protein as specified in the legend 
to Fig. 3. The assay was performed under the standard assay conditions 
and in the presence of 1 mM Co 2+ and 2 mM Mg 2+. Cytosols from 
various tissues (1 mg/ml)  were immunoprecipitated by incubation with 
rabbit anti-fyn or rabbit anti-lyn antibodies (10 p.g/ml) for 1 h at 4°C 
and following addition of protein A sepharose overnight. The CytPTK 
activity was determined to the supernatant before and after immuno- 
precipitation. 
3.5. Comparison of capacity of cytosol and the plasma 
membrane compartment to phosphorylate PolyGlu4Tyr 
In this set of experiments, both of the cytosol and the 
Triton-soluble membranal compartment were analyzed with 
all three supporting divalent cations (Mn 2+, Co 2+ and 
Mg 2+ ), and at sufficiently high concentrations of ATP and 
PolyGlu4Tyr. The specific activity (per /zg protein) was 
determined. The results obtained for several representative 
tissues are summarized in Table 2. 
As can be seen in Table 2, tissue cytosols contain 
appreciable amounts of PolyGlu4Tyr phosphorylating ca- 
pacity. This amounted to 11-18% of total, for liver, 
cardiac and adipose tissue and reaches much higher values 
for spleen or kidney tissues (26% and 49% of total respec- 
tively, Table 2). Thus, PTK activity in rat cytosols is not 
rate-limiting. 
3.6. Staurosporine as a specific marker for CytPTKs 
Table 3 summarizes the IC50 values for staurosporine, 
quercetin and genestein on cytosolic PTKs versus Triton- 
extractable membranal CytPTKs from three representative 
tissues. As with CytPTKs, quercetin and genestein, inhib- 
ited M-PTKs at micromolar concentrations and did not 
demonstrate a significant preference for either toward 
membranal or cytosolic PTKs. In contrast, cytPTKs were 
exclusively and exquisitely sensitive to staurosporine at the 
nanomolar concentration range. 
Table 3 
Inhibition of CytPTK and membranal PTK activities from different 
tissues 
Tissue Inhibitors IC50 values (/~M) 
Cytosolic PTKs Triton-soluble 
membranal PTKs 
Adipose Staurosporine 0.022 -t- 0.005 2.1 + 0.4 
Quercetin 18.0 + 2.0 6.0 + 0.8 
Genistein 105 + 2.0 190 ___ 10 
Liver Staurosporine 0.021 _+ 0.006 4.5 _+ 0.5 
Quercetin 3.2 +_ 1.0 8.0 + 0.9 
Genistein 45.0 + 15 200 + 15 
Kidney Staurosporine 0.023 + 0.05 1.5 -+ 0.3 
Quercetin 2.3 + 0.5 8.0 _+ 1.2 
Genistein 12.5 +4.1 210-t- 10 
InsRTK Staurosporine - 1.2 _+ 0.2 
Quercetin - 2.8 5:0.5 
Genistein - > 100 
CytPTK and membranal PTK solubilized in Triton X-100 from different 
rat tissues, and InsRTK were submitted to tyrosine kinase inhibitors. 
CytPTK and membranal PTK activity were measured in the presence of 1 
mM cobalt, 1 mM magnesium and 1 mM manganese. InsRTK was 
measured in the presence of 2 mM manganese and l0 mM magnesium. 
3. 7. Fyn and Lyn in tissue cytosols 
To evaluate whether Fyn and Lyn comprise a consider- 
able fraction of the intracellular CytPTK activity, we ap- 
plied an immunoprecipitation technique and determined 
the activity remaining in solution subsequent to precipita- 
tion with anti-Fyn or anti-Lyn. The results indicate that 
anti-Fyn and anti-Lyn immunoprecipitated a negligible 
fraction of the total PolyGlu4Tyr phosphorylating activity 
(Table 4). CytPTK activity was also estimated in the 
fraction immunoprecipitated by a Lyn or a Fyn, by mea- 
suring the transfer of 32p from [ y-32 P]ATP to PolyGlu4Tyr. 
It represents only less than 2% of the total cytosolic 
phosphotransferase activity (not shown). This remained 
valid even for tissue cytosols (e.g., from spleen, brain, 
liver, kidney) in which an abundant quantity of Fyn or Lyn 
had been detected by Western blot analyses [16-21] (and 
other refs. not shown). Thus, the src-related CytPTKs, 
while appearing as general markers for many tissue cy- 
tosols, provide only minimal contribution to the overall 
intracellular-PTK activity. 
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4. Discussion 
With the recognition that PolyGluaTyr is a good exoge- 
nous substrate for most PTKs [22-24] (and reviewed in 
Ref. [11]), we were able to study several quantitative and 
qualitative parameters of CytPTK originating from a large 
variety of rat tissues. More importantly, use of this sub- 
strate allowed us to find a specific marker for CytPTK, 
distinguished them from plasma membrane PTKs. With 
respect o divalent ions, CytPTK's activity in general is 
supported by Co 2+ > Mn 2+ > Mg 2+, and not by Zn 2+ or 
Ca 2+. But this feature is like that of intrinsic plasma 
membrane PTKs such as the InsRTK, whose activity is 
supported by Mn 2+, or to the EGF receptor whose activity 
is supported by Co 2+ [25]. There are also no basic differ- 
ences with respect o the nucleoside-triphosphate donors. 
Both classes of PTKs utilize ATP best as the phosphate 
donor but also show some affinity to other related nucleo- 
side 3'-phosphate molecules [11]. Our findings of most 
interest were (a) the relatively high PTK capacity of high 
speed supernatants, (b) the 3- to 13-fold variation of 
CytPTK activities found among tissue cytosols, (c) the 
realization that general CytPTK tissue markers uch as Fyn 
or Lyn possess negligible intracellular PolyGiuaTyr phos- 
phorylating capacity, and (d) that staurosporine is a spe- 
cific inhibitory marker of CytPTKs. 
Phosphotyrosine in cells comprises less than 0.1% of 
the combined amount of phosphoserine and phosphothreo- 
nine [26], indicating that there is either very little substrate 
or very little phosphorylating enzyme. We have found that 
there is a significant amo~ant of cytosolic PTK. It should be 
noticed, however, that tyrosine moieties in proteins are less 
abundant and less exposed to the protein surface than are 
Ser/Thr residues, but this does not seem to fully account 
for the low level of phesphotyrosine found in cells. The 
major rate-limiting factors, therefore, appear to be re- 
stricted levels of substr~tes and an efficient intracellular 
'terminating' system (i.e., active cellular PTPases) which 
hydrolyses phosphotyrosine moieties of proteins back to 
tyrosines. Under experimental conditions in which PTPase 
activity is inhibited, a m~tssive phosphorylation f tyrosine 
moieties in cells has been observed [27,28]. 
The specific activity of CytPTKs showed a 3- to 13-fold 
variation between the tissues (Fig. 3). Tissues of lym- 
phoidic origin such as spleen and thymus are rich sources 
of CytPTK, as are also kidney, adrenal, lung and intestine 
smooth muscle tissues. In contrast, skeletal and cardiac 
muscle are very low in CytPTK activity (Fig. 3). Taken 
together, the results suggest the participation of CytPTK in 
immune response mechanisms [1-3]. Physiological func- 
tions that are carried out by cardiac and skeletal muscles, 
on the other hand, appear to require only discrete cytosolic 
PTK activity. 
It should be noted that under our PTK-assay conditions, 
no significant desphosphorylation of phosphorylated- 
PolyGluaTyr occurs (not shown) in the presence of vana- 
date, which inhibits PTPases, there is an increase in the 
specific activities of many tissue PTKs [4-6]. This in- 
crease is attributed to PTK activation rather than inhibition 
of dephosphorylation f the phosphorylated PolyGluaTyr 
(see Ref. [6]). 
The CytPTKs Lyn and Fyn were found to be present in 
almost all tissue cytosols, some of which (i.e., Fyn in liver 
pancreas, kidney and smooth muscle) seem to contain 
large quantities of these enzymes. Nevertheless, anti-Fyn 
immunoprecipitated a negligible amount (less than 2%) of 
the total cytosolic PolyGlu4Tyr phosphorylating capacity 
(Table 4). The same applies to anti-Fyn. These results 
indicate that these general CytPTK markers, although pre- 
sent, contribute little (if at all) to the intracellular CytPTK 
activity. The bulk still remains to be discovered and char- 
acterized. 
Finally, we found here that staurosporine is a specific 
marker for CytPTK, being ~ 100-fold more potent an 
inhibitor of CytPTKs than intrinsic receptor and non-recep- 
tor membranal PTKs. Staurosporine assisted us previously 
in determining that several insulin effects triggered by 
vanadate are mediated via a rat-adipocytic CytPTK. It was 
also used to demonstrate hat growth hormone facilitates 
its biological effects via non-receptor cytosolic PTK [29]. 
The basic conformational entities that make CytPTKs more 
sensitive to staurosporine are currently being studied. With 
respect o this, Songyang and associates found recently 
that CytPTKs prefer peptide substrates having ileu or val 
at the -1  position to the phosphorylated tyrosine and a 
Glu, Gly or Ala at the + 1 position. In contrast, receptor 
family PTK select peptides with Glu at the -1  position 
and large hydrophobic amino acids at the + 1 position 
[30]. This may suggest a basic difference in the substrate 
binding domain of CytPTK as opposed to M-PTKs and 
can give some explanation to the tighter affinity of stau- 
rosporine toward CytPTKs. Although staurosporine (as 
well as quercetin and genestein) are competitive with ATP, 
rather than with the substrate, both the ATP and the 
substrate binding domains are mutually dependent and in 
close proximity to each other [31-33]. 
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